
Consider the four “P’s” of generic drugs that support the case for wider adoption of generics in the health system and beyond.
Importance of transparency when addressing a changing 340B environment.
By
Date
September 12, 2022
By: Heather Easterling and Andrew Wilson
Read time: 1 minute
Since 2020, drug manufacturers have implemented policies restricting the purchase of 340B-priced drugs for covered entities when dispensing through contract pharmacies and the result is contributing to financial losses for safety-net hospitals.
Watch the 340B Tips, Tricks, and Traps webinar as we explore this ever-changing environment and how transparency is at the center of it all.